New Phase 1 Results for ALN-KHK Presented at the American Diabetes Association’s 84th Scientific Sessions

26 Jun, 2024 New Phase 1 Results for ALN-KHK Presented at the American Diabetes Association’s 84th Scientific Sessions

We presented additional positive interim results for an ongoing Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase in development for the treatment of type 2 diabetes, at the American Diabetes Association’s 84^th Scientific Sessions. Our investigational therapeutic showed an encouraging safety and tolerability profile and target engagement in the single ascending dose part of the study in healthy overweight to obese adults.

Maratos-Flier, et al. “ALN-KHK, an Investigational RNA Interference Therapeutic, Successfully Targets Hepatic Ketohexokinase in a Single Ascending Dose Study of Overweight to Obese Adults”